Novo Nordisk's once-weekly Ozempic, or semaglutide injection, was approved by the FDA for use in adult patients with type 2 diabetes as an adjunct to exercise and diet for the improvement of glycemic control.
Novo's once-weekly drug for type 2 diabetes approved by FDA
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.